Recent research has revealed that GLP-1 obesity medications like Ozempic, Wegovy, and Mounjaro can result in significant muscle loss during weight loss, with around one-third of the weight shed coming from muscle rather than fat. In a clinical trial involving 102 participants, primarily women, those who received apitegromab alongside their obesity medication were able to maintain approximately 1.9 kg, or 55% more muscle, compared to those who received a placebo. This finding is particularly relevant as many users of GLP-1 drugs report changes in body shape, including a sagging appearance referred to as 'Ozempic butt'. Apitegromab, which is not yet widely available, works by blocking a protein that contributes to muscle breakdown. While the results are promising, experts like Dr. Marie Spreckley from Cambridge University emphasize the need for larger, more comprehensive studies to validate these findings and assess their long-term health implications. Additionally, maintaining muscle mass requires a combination of strength training and adequate protein intake, which is crucial for overall health during weight loss.